Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 2
2006 2
2007 1
2008 1
2009 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

8 results
Results by year
Filters applied: . Clear all
Page 1
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Lynch TJ, et al. Among authors: haserlat sm. N Engl J Med. 2004 May 20;350(21):2129-39. doi: 10.1056/NEJMoa040938. Epub 2004 Apr 29. N Engl J Med. 2004. PMID: 15118073 Free article.
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.
Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MG, Baselga J, Ochs JS, Haber DA. Bell DW, et al. Among authors: haserlat sm. J Clin Oncol. 2005 Nov 1;23(31):8081-92. doi: 10.1200/JCO.2005.02.7078. Epub 2005 Oct 3. J Clin Oncol. 2005. PMID: 16204011 Clinical Trial.
Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis.
Smolen GA, Muir B, Mohapatra G, Barmettler A, Kim WJ, Rivera MN, Haserlat SM, Okimoto RA, Kwak E, Dahiya S, Garber JE, Bell DW, Sgroi DC, Chin L, Deng CX, Haber DA. Smolen GA, et al. Among authors: haserlat sm. Cancer Res. 2006 Apr 1;66(7):3452-5. doi: 10.1158/0008-5472.CAN-05-4181. Cancer Res. 2006. PMID: 16585167 Free article.
Prevalence and functional analysis of sequence variants in the ATR checkpoint mediator Claspin.
Zhang J, Song YH, Brannigan BW, Wahrer DC, Schiripo TA, Harris PL, Haserlat SM, Ulkus LE, Shannon KM, Garber JE, Freedman ML, Henderson BE, Zou L, Sgroi DC, Haber DA, Bell DW. Zhang J, et al. Among authors: haserlat sm. Mol Cancer Res. 2009 Sep;7(9):1510-6. doi: 10.1158/1541-7786.MCR-09-0033. Epub 2009 Sep 8. Mol Cancer Res. 2009. PMID: 19737971 Free PMC article.
Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts.
Bell DW, Kim SH, Godwin AK, Schiripo TA, Harris PL, Haserlat SM, Wahrer DC, Haiman CA, Daly MB, Niendorf KB, Smith MR, Sgroi DC, Garber JE, Olopade OI, Le Marchand L, Henderson BE, Altshuler D, Haber DA, Freedman ML. Bell DW, et al. Among authors: haserlat sm. Int J Cancer. 2007 Dec 15;121(12):2661-7. doi: 10.1002/ijc.23026. Int J Cancer. 2007. PMID: 17721994 Free PMC article.
Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas.
Kwak EL, Jankowski J, Thayer SP, Lauwers GY, Brannigan BW, Harris PL, Okimoto RA, Haserlat SM, Driscoll DR, Ferry D, Muir B, Settleman J, Fuchs CS, Kulke MH, Ryan DP, Clark JW, Sgroi DC, Haber DA, Bell DW. Kwak EL, et al. Among authors: haserlat sm. Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4283-7. doi: 10.1158/1078-0432.CCR-06-0189. Clin Cancer Res. 2006. PMID: 16857803 Free PMC article.
Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR.
Cohen EE, Lingen MW, Martin LE, Harris PL, Brannigan BW, Haserlat SM, Okimoto RA, Sgroi DC, Dahiya S, Muir B, Clark JR, Rocco JW, Vokes EE, Haber DA, Bell DW. Cohen EE, et al. Among authors: haserlat sm. Clin Cancer Res. 2005 Nov 15;11(22):8105-8. doi: 10.1158/1078-0432.CCR-05-0926. Clin Cancer Res. 2005. PMID: 16299242 Free article.